TABLE 2.
Baseline demographics and disease characteristics of patients in the dose expansion cohort (part 2)
| Parameters | TV 2.0 mg/kg (N = 17) |
|---|---|
| Age (years) | |
| Mean (standard deviation) | 48.1 (11.3) |
| Median (range) | 47.0 (33.0–66.0) |
| Age, years (%) | |
| <50 | 10 (58.8) |
| ≥50 to ≤65 | 5 (29.4) |
| >65 | 2 (11.8) |
| Weight (kg) | |
| Mean (standard deviation) | 53.5 (11.7) |
| Median (range) | 53.0 (30.0–72.0) |
| Histology type, n (%) | |
| Squamous cell carcinoma | 9 (52.9) |
| Adenocarcinoma | 8 (47.1) |
| ECOG performance status at baseline, n (%) | |
| 0 | 9 (52.9) |
| 1 | 8 (47.1) |
| Metastatic disease at screening, n (%) | |
| Yes | 15 (88.2) |
| No | 2 (11.8) |
| Recurrent disease at screening, n (%) | |
| Yes | 13 (76.5) |
| No | 4 (23.5) |
| Prior lines of systemic therapy in the recurrent or metastatic setting, n (%) | |
| 1 line | 8 (47.1) |
| 2 lines | 9 (52.9) |
| Bevacizumab in combination with chemotherapy doublet as first‐line systemic regimen, n (%) | |
| Yes | 8 (47.1) |
| No | 9 (52.9) |
| Response to last systemic regimen, n (%) | |
| Yes | 4 (23.5) |
| No | 11 (64.7) |
| Not known | 2 (11.8) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; TV, tisotumab vedotin.